BioSpace News Archive

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the virtual BofA Securities 2020 Health Care Conference. Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals, is scheduled to present a corporate overview on Wednesday, May

May 6, 2020 12:00 UTC Clinically relevant reductions in liver fat content, insulin resistance and fibroinflammation markers observed with AXA1125 along with favorable tolerability, supporting its potential to be a first-line NASH therapy Greater activity in key markers seen among subjects with type 2 diabetes receiving AXA1125 Company plans to engage with FDA regarding IND submission for AXA1125, proposed Phase 2b clinical trial in adult NASH and pediatric dev

- Anticipates Early Data Readout for Phase 2b Study of PTI-125 in Alzheimer’s Disease - - Approximately $2.9 Million in NIH Research Grants Awarded in 2020 - - Open-Label Study of PTI-125 Initiated in Alzheimer’s Disease -

Hologic, Inc. announced that the Company will present at these upcoming virtual investor conferences

- New corporate name, Cardiff Oncology, reflects the Company’s mission and commitment to turning the tide on cancer by developing new treatment options for cancer patients - Effective May 8th, Dr. Thomas Adams will transition his role from Chairman and CEO to Executive Chairman and Dr. Mark Erlander will assume the role of CEO - Changes mark an important milestone in the Company’s evolution and advancing development of onvansertib in cancer indications with the greatest medic

Twist Bioscience Corporation (Nasdaq: TWST) today reported it has identified competitive antibodies to SARS-CoV-2, the virus that causes COVID-19, which could potentially be used for diagnostic tests or therapeutic treatments.

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Mark Pruzanski, M.D., President and Chief Executive Officer of Intercept, will present at the Bank of America Merrill Lynch Virtual Global Healthcare Conference on Wednesday, May 13, 2020 at 2:20 p.m. ET. A live webcast of the event will b

Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, announced today a change in the format of its Annual Meeting of Shareholders (“Annual Meeting”) from an in-person to a virtual-only meeting, via webcast, due to the emerging public health impact of the coronavirus pandemic (COVID-19) and to support the health and well-being of the Company’s shareholders, employees and their families. As previously announced, the Annual M

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Preston Klassen , MD, MHS, the Company’s Executive Vice President, Head of Research & Development, is scheduled to participate in a virtual fireside chat at the Bank of America Securities 2020 Healthcare Conference on Wednesday, May 13 , at 10:20 AM ET ( 7:20 AM PT ).

As states open, Premier Medical Laboratory Services provides unprecedented testing capacity for South Carolina